Immunis is a clinical stage biotech developing a novel stem cell-derived biologic, a differentiated multi-active therapy to treat the complex muscle wasting and metabolic impairment associated with age-driven immune decline. Immunis is launching a Phase 2 trial targeting sarcopenic obese elderly in early 2025 and planning a Phase 2b trial to treat muscle trophy in sarcopenic elderly with knee osteoarthritis in mid-2025. The value proposition is the potential to restore strength and function, energy, and a healthier body composition to older adults. Mark Cabato is the Chief Business Officer responsible for business development, strategy, and finance